Standard BioTools Inc. (LAB) vs Vanda Pharmaceuticals Inc. (VNDA)

A side-by-side comparison of Standard BioTools Inc. and Vanda Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — LAB vs VNDA

growth of $100 · dividends reinvested · last 10y
LAB -90.5% (-20.9%/yr)VNDA -72.8% (-12.2%/yr)VNDA compounded faster over this window
050100150Start $10020182020202220242026$10$27
LAB VNDA

LAB vs VNDA: by the numbers

  • •LAB is the larger company ($283M vs $272M market cap).
  • •Both run net losses; LAB's is the smaller (-103.29% vs -127.41% net margin).
  • •Both shrank revenue over the past five years; VNDA's decline was smaller (-3.56% vs -10.62% CAGR).

Metrics side by side

Valuation

MetricLABVNDA
P/S ratio3.341.26
P/B ratio0.521.23

Profitability

MetricLABVNDA
Gross margin49.14%92.82%
Operating margin-109.34%-69.95%
Net margin-103.29%-127.41%
ROE-16.18%-124.83%
ROIC-14.06%-74.73%

Growth (annualized)

MetricLABVNDA
Revenue CAGR (5Y)-10.62%-3.56%
Total return CAGR (5Y)-32.98%-23.91%

Frequently asked

Which has grown faster, LAB or VNDA?
Neither grew: over the past five years both shrank revenue, with VNDA's decline the smaller — LAB at a -10.62% CAGR versus VNDA at -3.56%.
How have LAB and VNDA total returns compared?
Over the past 10 years, LAB delivered -20.93% and VNDA delivered -11.90% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.